Interestingly, SET7/9 is overexpressed in prostate cancer (ref. 23 and Supplemental Figure 1, C and D), and SET7/9 protein levels positively correlate with the Gleason score (Supplemental Figure 1E), supporting the notion that enhanced posttranslational modification of JMJD2A by SET7/9 might have relevance for human prostate cancer development. Here, KDM4A is linked to prostate cancer.